# US 2023/0390333 A1 · Method for maximizing coronavirus killing activity of high-density lipoproteins, and pharmaceutical composition for preventing or treating covid-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390333 A1
- Document ID: US20230390333A1
- Status: Published application
- Kind: A1
- Application number: 18/253,999
- Filed: 2021-12-22
- Published: 2023-12-07
- Earliest claimed: 2021-01-13
- Assignees: Raydel Korea Co., Ltd.
- Applicants: Raydel Korea Co., Ltd.
- Inventors: Kyung-Hyun CHO
- Web page: https://patentgrep.com/patent/US20230390333A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61P 31/14: for RNA viruses
- C12Q 1/44: involving esterase
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2333/775: Apolipopeptides
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated native HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.

## Claims

### Claim 1

A pharmaceutical composition for preventing and treating corona 19 infection (COVID-19) comprising HDL (high-density lipoprotein) and an HDL glycation inhibitor as active ingredients.

### Claim 2 (depends on 1)

The pharmaceutical composition for preventing and treating COVID-19 according to claim 1, wherein the HDL is non-glycated HDL.

### Claim 3 (depends on 1)

The pharmaceutical composition for preventing and treating COVID-19 according to claim 1, wherein the HDL is isolated from human serum.

### Claim 4 (depends on 1)

The pharmaceutical composition for preventing and treating COVID-19 according to claim 1, wherein the HDL has the ability to kill coronavirus (SARS-Co-V-2).

### Claim 5 (depends on 4)

The pharmaceutical composition for preventing and treating COVID-19 according to claim 4, wherein the HDL has the ability to kill coronavirus (SARS-Co-V-2) by paraoxonase activity or preventing macrophage phagocytosis of acetylated LDL.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The pharmaceutical composition for preventing and treating COVID-19 according to, claim 1 wherein the HDL glycation inhibitor prevents reduction in killing ability of HDL against coronavirus (SARS-Co-V-2) due to glycation.

### Claim 8

A method for maximizing coronavirus killing activity of HDL (high-density lipoprotein), said method comprising administering HDL with an HDL (high-density lipoprotein) glycation inhibitor.

### Claim 9 (depends on 8)

The method for maximizing the coronavirus killing activity of HDL according to claim 8, wherein the HDL glycation inhibitor prevents reduction in killing ability of HDL against coronavirus (SARS-Co-V-2) due to glycation.

### Claim 10

(canceled)

### Claim 11

A method for screening a pharmaceutical composition for preventing or treating corona 19 infection (COVID-19) consisting of the following steps:
comparing the degree of HDL glycation using the HDL glycation induction model as a control group and the HDL glycation induction model treated with a candidate drug as an experimental group; and
determining that the treated candidate drug is effective against COVID-19 when the degree of glycation of HDL is low in the experimental group treated with the candidate drug compared to the HDL glycation induction model control group.

### Claim 12 (depends on 11)

The method for screening a pharmaceutical composition for preventing or treating COVID-19 according to claim 11, wherein the step of comparing the degree of glycation of HDL further includes a step of comparing and evaluating at least one activity of paraoxonase activity and activity of preventing macrophage phagocytosis of acetylated LDL.

### Claim 13 (depends on 12)

The method for screening a pharmaceutical composition for preventing or treating COVID-19 according to claim 12, wherein if at least one activity of the paraoxonase activity and the activity of preventing macrophage phagocytosis of acetylated LDL is high in the experimental group treated with the candidate drug compared to the HDL glycation induction model control group, the treated candidate drug is determined to be effective against COVID-19.

### Claim 14

A method for predicting prognosis of corona 19 infection (COVID-19) consisting of the following steps:
comparing the degree of HDL glycation using the HDL glycation induction model as a control group and the HDL isolated from a blood sample of a test subject as an experimental group; and
determining that the prognosis of COVID-19 is good when the degree of glycation in the experimental group HDL isolated from the blood sample is low compared to the HDL glycation induction model control group.

### Claim 15 (depends on 14)

The method for predicting prognosis of COVID-19 according to claim 14, wherein the step of comparing the degree of glycation of HDL further includes a step of comparing and evaluating at least one activity of paraoxonase activity and activity of preventing macrophage phagocytosis of acetylated LDL.

### Claim 16 (depends on 15)

The method for predicting prognosis of COVID-19 according to claim 15, wherein if at least one activity of the paraoxonase activity and the activity of preventing macrophage phagocytosis of acetylated LDL is high in the experimental group HDL isolated from the blood sample compared to the HDL glycation induction model control group, it is determined that the prognosis of COVID-19 is good.

### Claim 17 (depends on 11)

The method for screening a pharmaceutical composition for preventing or treating COVID-19 according to claim 11, wherein the HDL glycation induction model is prepared by treating HDL with any one or two or more sugar compounds selected from the group consisting of fructose, glucose and galactose.

### Claim 18 (depends on 14)

The method for predicting the prognosis of COVID-19 according to claim 14, wherein the HDL glycation induction model is prepared by treating HDL with any one or two or more sugar compounds selected from the group consisting of fructose, glucose and galactose.
